AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01291693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Counseling
Description: At three time-points, participants receive counseling by health professionals trained in Motivational Interviewing based counseling. To assure that both interventions do not differ in their content, individual manuals generated by a software program are used. Counseling will be face-to-face during the hospital stay, and by phone one and three months later.
Study NCT01291693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-generated feedback letters
Description: At three time points, participants receive feedback letters, tailored to the stages of change according to the TTM, and generated by a computer software program. The first letter is handed out during their hospital stay and includes normative feedback. One and three months later, participants receive ipsative feedback letters by mail.
Study NCT01544413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sentinel lymph node biopsy
Description: During the operation, endoscopic marking was perfomed using Tc 99m HSA and indocyanine green around tumor. Then we identify the sentinel lymph node with laparoscopic probe. Laparoscopic sentinel lymph nodes were dissedted and evaluated them at the backtable in the operating room.
Study NCT02333149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Children \<40 kg will take one tablet, melatonin 3 mg, oral, 30 - 60 minutes prior to bedtime.~Children ≥40 kg will take two tablets, melatonin 3 mg, oral, 30-60 minutes prior to bedtime.
Study NCT02333149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo frequency and volume are identical to the experimental arm
Study NCT05640206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: i-PRF
Description: Arthrocentesis performed with two-needle technique, and then injection of i-PRF intra-articularly
Study NCT05640206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthrocentesis
Description: Arthrocentesis performed with two-needle technique
Study NCT00313768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel + carboplatin + bevacizumab
Description: paclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles
Study NCT00313768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin + paclitaxel + bevacizumab + PF-3512676
Description: carboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles
Study NCT02251132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV low 1
Study NCT02251132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV low 2
Study NCT02251132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV medium
Study NCT00646529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide (Pulmicort)
Study NCT00324324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin hydrochloride
Description: Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
Study NCT00305773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally once daily
Study NCT00305773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally three times daily
Study NCT02027285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortified milk
Description: FortifiedUltra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) produced by Granarolo s.p.a. supplemented with long chain unsaturated fatty acids DHA (Docosahexaenoic acid) +EPA (Eicosapentaenoic acid), vitamin D, B12, B6, B9, E,C, Zinc and Selenium versus placebo Ultra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) of the same manufacturer.~The nutrients added are: DHA + EPA 1.4 mg/ml; vitamin D3 0.068 mcg/ml; B6 6.4 mcg/ml; B12 0.01 mcg/ml; B9 (folic acid) 0.80 mcg/ml; vitamin E 0.05 mg/ml; vitamin C 0.19 mg/ml; Zinc 0.04 mg/ml; Selenium 0.22 mcg/ml. The protein content of the milk is 0.04 g/ml.
Study NCT02027285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: fortified milk
Description: FortifiedUltra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) produced by Granarolo s.p.a. supplemented with long chain unsaturated fatty acids DHA (Docosahexaenoic acid) +EPA (Eicosapentaenoic acid), vitamin D, B12, B6, B9, E,C, Zinc and Selenium versus placebo Ultra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) of the same manufacturer.~The nutrients added are: DHA + EPA 1.4 mg/ml; vitamin D3 0.068 mcg/ml; B6 6.4 mcg/ml; B12 0.01 mcg/ml; B9 (folic acid) 0.80 mcg/ml; vitamin E 0.05 mg/ml; vitamin C 0.19 mg/ml; Zinc 0.04 mg/ml; Selenium 0.22 mcg/ml. The protein content of the milk is 0.04 g/ml.
Study NCT02309372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beating the Blues
Description: Computerized depression treatment intervention
Study NCT04898088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells Transplantation
Description: Mesenchymal Stem Cells Transplantation applied as three intravenous infusions with 30 days intervals
Study NCT02022644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoliposomal irinotecan
Description: The drug named here (nanoliposomal irinotecan) will be used in varying amounts, based on tumor volume.
Study NCT02251132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV high 1
Study NCT00324324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
Study NCT01806753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent midazolam/propofol injection controlled by endoscopist
Description: In this arm1, sedation during endoscopic submucosal dissection is controlled by endoscopists.~First, pethidine 50 mg with midazolam 0.05 mg/kg are injected in a bolus fashion.~When the patient seems to be discomfort or the patient's movements were observed, endoscopists should check the Modified Observer Assessment of Alertness/Sedation (MOAAS).~If MOAAS is 5 or 6, propofol 0.25 mg/kg will be injected. Otherwise, pethidine 12.5 mg will be injected.
Study NCT01806753 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous propofol infusion with opioid administration
Description: In this arm2, sedation during endoscopic submucosal dissection is controlled by anesthesiologists.~First, remifentanil 0.5 ug/kg with propofol 0.5 mg/kg are injected in a bolus fashion.~Then, remifentanil 0.08 ug/kg/min and propofol 2 mg/kg/h are infused continuously.~When the patient seems to be discomfort or the patient's movements were observed, anesthesiologists should check the MOAAS.~If MOAAS is 5 or 6, infusion rate of propofol will be increased by 0.5 mg/kg/h. Otherwise, infusion rate of remifentanil will be increased by 0.02 ug/kg/min.
Study NCT04047433 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: screening for single nucleotide polymorphism
Description: samples from both arms will be tested for a set of single nucleotide polymorphism
Study NCT02251132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV high 2
Study NCT02251132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV low
Study NCT04047433 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: whole exome sequencing
Description: samples from arm #1 (women with external anal sphincter) will be tested for identifying specific genetic mutation
Study NCT03310554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 26cm suspended overlength biliary stents
Description: The test group will be placed 26cm suspended overlength biliary stents in introhepatic bile duct in ERCP
Study NCT03310554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 30cm suspended overlength biliary stents
Description: The test group will be placed 30cm suspended overlength biliary stents in introhepatic bile duct in ERCP
Study NCT02251132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir high
Study NCT03310554 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ordinary plastic biliary stents
Description: The control group will be placed ordinary plastic biliary stents in bile duct in ERCP
Study NCT00385242 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron emission tomography: FDG viability imaging
Description: FDG PET viability imaging
Study NCT00385242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PET imaging
Description: PET viability imaging
Study NCT00535223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Based Exposure Therapy
Description: GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking.
Study NCT00535223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Present Centered Group Therapy
Description: Present Centered Group Therapy includes psych-education about PTSD and a problem solving here and now focus.
Study NCT01320462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smoking cessation counselling group
Description: The smoking-cessation program has three components; structured preoperative counseling, pharmacotherapy with varenicline for three months, and referral to the quit line (Smokers' Helpline) for proactive telephone counseling and follow up
Study NCT01320462 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group:
Description: Interventions in the control group will be a brief advice regarding smoking cessation and provision of the quit line's information.
Study NCT04311424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C Tirzepatide
Description: Administered SC.
Study NCT03597958 — intervention group
Intervention type: GENETIC
Intervention: Next generation sequencing (NGS)
Description: NGS panel, whole exome / genome sequencing (WES/WGS), transcriptome analysis
Study NCT03318354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Olmesartan Medoxomil Tablets 40 mg
Study NCT03318354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daiichi Sankyo Inc's Benicar Tablets 40 mg
Study NCT01114165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detection of microbial DNA in blood by SeptiFast Test
Description: The SeptiFast Test is a multiplex polymerase chain reaction (PCR) test that can detect nucleic acids from the most common pathogens (approximately 90%) responsible for hospital-associated bacteremia and takes approx. 6 hours to perform
Study NCT01114165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pathogen detection by blood culture
Description: Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling
Study NCT00743327 — intervention group
Intervention type: DRUG
Intervention: Pioglitazone
Description: 45mg capsule, once daily for 1 year
Study NCT03352323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Description: RLD
Study NCT02251132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled erythromycin
Study NCT01656590 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding
Description: 1. High Protein and Moderate Carbohydrate Nutrition designed by our nutritionist for every patient based on his/her nutrition requirements, age \& gender~2. 500 cc Formula - Nutren Replete with Fiber overnight \[8 hours\] via gastrostomy tube~3. Conditioning Exercise once daily
Study NCT03106220 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: home exercise program
Study NCT03106220 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: encourage walking and physical therapy per standard care.
Study NCT01297140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questioning
Description: Patients will be screened by questioning them and their caregiver and from the results of the clinical examination and the biological and neuroradiological tests habitually carried out in cases of dementia and following accepted procedures.
Study NCT03793582 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ApneaLink Type III portable sleep study
Description: Type III portable sleep study
Study NCT04291391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: North American-type diet
Description: All groups will receive an isocaloric diet for 4 weeks composed of 48% of energy as carbohydrate, 17% as protein, and 35% as lipid (12.5% of saturated fat, 13% of monounsaturated fat, and 6% of polyunsaturated fat), designed to reflect as closely as possible current macronutrient intake averages in North America/Canada.America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein)
Study NCT01709851 — intervention group
Intervention type: DEVICE
Intervention: Vascular microdialysis using the GMD-system
Description: Glucose levels will be monitored by means of vascular microdialysis using the GlucoMen(R)Day system
Study NCT01709851 — intervention group
Intervention type: DEVICE
Intervention: Vascular and subcutaneous microdialysis using the GMD-system
Description: Glucose levels will be monitored by means of vascular and subcutaneous microdialysis using the GlucoMen(R)Day system
Study NCT03282942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training group
Description: Individuals in the strength training group will perform exercises based on exercises with free weights and equipment, for upper and lower limbs with a weekly frequency of three times for twelve weeks. The periodization will start with 2 sets, 15 - 20 repetitions, passive rest of 120 seconds, exercises performed alternating by segments and the intensity of 50% of maximum repetition. After twelve weeks the periodization will be finished with 3 sets, 8-12 repetitions, passive rest of 120 seconds, exercises performed alternated by segments and the intensity of 70% of maximum repetition.~The following exercises will compose the strength training protocol:~* Squatting~* Leg press~* Knee Extension~* Knee Flexion~* Supine Challenge~* High Pull~* Elbow flexion~* Extension of elbows~* Development~* Abdominal
Study NCT03282942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training Group
Description: Individuals in the aerobic training group will perform aerobic treadmill exercise three times a week for twelve weeks. The training prescription will be performed through the percentage of maximum oxygen consumption with intensity in 60% to 80% with an average duration of 50 minutes of continuous exercise.
Study NCT01865539 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Custom Foot Orthotic
Description: Custom foot orthotic with custom design pads
Study NCT01865539 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Orthotic
Description: Leather insert without the custom design pads
Study NCT04324060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol + rhTPO (recombinant human thrombopoietin injection)
Description: subcutaneous injection, 300U/kg/d×14d every month，stop if the PLT≥100×10e9/L or increased >50×10e9/L, total course is 6 months
Study NCT04324060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Danazol + sodium chloride
Description: Danazol 0.2g tid po+ control (sodium chloride)
Study NCT00864149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg Tablets, single dose
Description: A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
Study NCT00864149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coreg® 12.5 mg Tablets , single dose
Description: B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fed conditions
Study NCT03019939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Given PO or IV
Study NCT01256554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SSRS)
Description: Target dose of 18 or 24 Gy to spine in single session of radiation.
Study NCT01256554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
Study NCT01620710 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: hypofractionated helical IMRT
Description: hypofractionated helical IMRT of the prostate bed, 18 x 3 Gy
Study NCT01620710 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: hypofractionated helical IMRT
Description: helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
Study NCT01355094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KCI AbThera
Description: The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing.
Study NCT01355094 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stampede VAC
Description: The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing.
Study NCT03819608 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real iTBS
Description: Intermittent Theta Burst Stimulation (iTBS) is a form of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
Study NCT03819608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real iTBS
Description: Intermittent Theta Burst Stimulation (iTBS) is a form of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
Study NCT03819608 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: real APT
Description: APT-III is an attention processing training program
Study NCT03819608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: real APT
Description: APT-III is an attention processing training program
Study NCT03819608 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: placebo APT
Description: computerized cognitive training
Study NCT03819608 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: placebo iTBS
Description: delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
Study NCT01609335 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: F-18 FDG
Description: One time intravenous administration of 17 millicurie (mCi) +/- 10%
Study NCT01609335 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: C-11 PiB
Description: One time intravenous administration of 10-20 mCi
Study NCT00791557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: IV drug given at weeks 1,2,14,22
Study NCT02238340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release oxycodone
Description: 10 o 20 mgrs of extended-release oxycodone ,started 12 hours before orthopaedic surgery
Study NCT02238340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended- release Oxycodone
Study NCT02238340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen